EUCTR2012-005275-14-NO
Active, not recruiting
Phase 1
Remission in rheumatoid arthritis – assessing withdrawal of disease-modifying antirheumatic drugs in a non-inferiority design - ARCTIC REWIND
Diakonhjemmet Hospital AS0 sites360 target enrollmentFebruary 4, 2013
ConditionsRheumatoid arthritis (RA)MedDRA version: 15.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
DrugsMethotrexate Pfizer 2,5 mg tabletterMetex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyteSalazopyrin EN 500 mg enterotabletterPlaquenil 200 mg filmdrasjerte tabletterArava 20 mg filmdrasjerte tabletterENBREL 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.Cimzia 200 mg injeksjonsvæske, oppløsningSimponi 50 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning.Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Rheumatoid arthritis (RA)
- Sponsor
- Diakonhjemmet Hospital AS
- Enrollment
- 360
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •a)Rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria (48\), Appendix 2\.
- •b)Male or non\-pregnant, non\-nursing female
- •c)\>18 years of age and \< 80 years of age
- •d)Disease duration less than five years at inclusion into ARCTIC REWIND, defined as time from first joint swelling
- •e)Sustained remission for \= 12 months according to DAS or DAS28, with documented remission status at a minimum of 2 consecutive visits during the last 18 months OR participation in the first ARCTIC trial
- •f)DAS \< 1\.6 and no swollen joints at inclusion OR participation in the first ARCTIC trial
- •g)Unchanged treatment with TNFi and/or synthetic DMARDs during the previous 12 months, with a stable or reduced dose of glucocorticosteroids OR participation in the first ARCTIC trial
- •h)Subject is capable of understanding and signing an informed consent form
- •i)Provision of written informed consent
- •Are the trial subjects under 18? no
Exclusion Criteria
- •a)Abnormal renal function, defined as serum creatinine \> 142 µmol/L in female and \> 168 µmol/L in male, or a GFR \< 40 mL/min/1\.73 m2
- •b)Abnormal liver function (defined as ASAT/ALAT \> 3 x upper normal limit), active or recent hepatitis, cirrhosis
- •c)Major co\-morbidities, such as severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3 or 4\) and/or severe respiratory diseases
- •d)Leukopenia and/or thrombocytopenia
- •e)Inadequate birth control, pregnancy, and/or breastfeeding
- •f)Indications of active TB
- •g)Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Outcome of Rheumatoid Arthritits patients following adjunct statin therapyHealth Condition 1: null- Diagnosed Rheumatoid Arthritis patients with active diseaseCTRI/2014/12/005233Kalinga Institute of Medical Sciences60
Active, not recruiting
Phase 1
REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritisEUCTR2016-002908-15-NLSint Maartenskliniek140
Recruiting
Not Applicable
The patient perspective on remission in rheumatoid arthritisarthritisRA10003816NL-OMON37359Vrije Universiteit Medisch Centrum24
Active, not recruiting
Phase 1
Remission Induction in Very Early Rheumatoid Arthritis (RIVERA):a comparison of etanercept plus methotrexate plus steroid with standard therapy - RIVERAEUCTR2006-001428-38-GBniversity Hospitals Birmingham NHS Foundation Trust20
Completed
Not Applicable
Remission Induction in Very Early Rheumatoid Arthritis: a comparison of etanercept plus methotrexate plus steroid with standard therapyISRCTN49682259Record Provided by the NHSTCT Register - 2007 Update - Department of Health20